# A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.

Source: https://onco.cc/trials/nct07052253/  
OnCo record `nct07052253` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Tinengotinib, Cadonilimab, Ivonescimab in hepatocellular carcinoma, run by Akeso, now recruiting.

## Summary

A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC. is a phase 2 interventional study registered as NCT07052253 by Akeso, with 100 participants planned, started 2025-07-18 and due to reach its primary completion in 2027-05-10. Interventions recorded: TT-00420 (tinengotinib), AK104, AK112. Conditions listed: Hepatocellular Carcinoma (HCC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07052253
- Phase: 2
- Setting: An Open-label, Multicenter, Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet in Patients With Advanced Hepatocellular Carcinoma.
- Sponsor: Akeso
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT07052253: https://clinicaltrials.gov/study/NCT07052253

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Cadonilimab](https://onco.cc/drugs/cadonilimab/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/), [Tinengotinib](https://onco.cc/drugs/tinengotinib/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct07052253.json